Physician profile
Amy Augustine
NPI 1508690827
$3,234.73
in general payments reported to CMS, 2019-2025
31 companies · $2,857 in 2025
The $2,857 reported for 2025 was more than what 96% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $378 · 2025: $2,857.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,235.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,234.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $398.65 | 2024-2025 | Rybelsus, Ozempic |
| Pfizer INC. | $300.24 | 2024-2025 | |
| Abbvie INC. | $243.26 | 2025 | |
| Vanda Pharmaceuticals INC. | $218.12 | 2024-2025 | Hetlioz, Fanapt |
| Bayer Healthcare Pharmaceuticals INC. | $209.61 | 2025 | |
| Astrazeneca Pharmaceuticals Lp | $206.65 | 2025 | Breztri, Airsupra, Farxiga |
| Indivior INC. | $174.33 | 2025 | Sublocade |
| Lilly USA, LLC | $142.16 | 2025 | Mounjaro, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $137.99 | 2024-2025 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $120.74 | 2024-2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $108.69 | 2025 | Jardiance, Ofev |
| Glaxosmithkline, LLC. | $103.95 | 2024-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Gilead Sciences, INC. | $97.45 | 2024-2025 | |
| Orexo US, INC. | $97.15 | 2025 | Zubsolv |
| Verona Pharma, INC. | $87.87 | 2025 | Ohtuvayre |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $81.09 | 2024-2025 | Caplyta |
| Lundbeck LLC | $65.72 | 2024-2025 | Rexulti |
| Kowa Pharmaceuticals America, INC. | $59.21 | 2024-2025 | Zoryve |
| Exact Sciences Corporation | $51.27 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Dexcom, INC. | $41.24 | 2025 | Dexcom G6 Transmitter |
| Alkermes, INC. | $41.20 | 2025 | Aristada, Lybalvi |
| E.R. Squibb & Sons, L.L.C. | $39.69 | 2024-2025 | Eliquis |
| Otsuka America Pharmaceutical, INC. | $31.77 | 2025 | Rexulti |
| Soleno Therapeutics, INC. | $29.32 | 2025 | Vykat Xr |
| Sumitomo Pharma America, INC. | $27.66 | 2025 | Gemtesa |
| Braeburn INC. | $27.04 | 2025 | Brixadi |
| Inspire Medical Systems, INC. | $25.00 | 2025 | Inspire |
| Corium, LLC | $20.92 | 2025 | Azstarys |
| Axsome Therapeutics, INC. | $17.58 | 2024 | Auvelity |
| Amgen INC. | $14.97 | 2025 | Otezla, Repatha |
| Seqirus USA INC | $14.19 | 2025 | Fluad, Flucelvax |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Augustine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.